Clinical Trial Update: AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating how to adapt Advagraf (tacrolimus extended-release) dosing after kidney transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Advagraf (tacrolimus)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Renal Transplantation | Phase 4 | Status: COMPLETED